Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ: SMMT )

19.91 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,534
Open 19.91
Bid (Size) 19.96 (10)
Ask (Size) 20.00 (1)
Prev. Close 19.91
Today's Range 19.91 - 19.91
52wk Range 2.100 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger
Via The Motley Fool
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga

Performance

YTD
+8.50%
+8.50%
1 Month
-2.88%
-2.88%
3 Month
+6.07%
+6.07%
6 Month
-12.29%
-12.29%
1 Year
+361.95%
+361.95%

More News

Read More
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown
Via Stocktwits
Palantir Extends Losses, Microsoft Slides: What's Driving Markets Monday?
Via Benzinga
Topics Stocks
Exposures US Equities
Is Summit Therapeutics a Millionaire Maker?
Via The Motley Fool
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
From Summit Therapeutics Inc.
Via Business Wire
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
Via Benzinga
2 Stocks That Could Soar Again in 2025
Via The Motley Fool
Why Summit Therapeutics Rocketed 584% in 2024
Via The Motley Fool
Earnings Scheduled For February 24, 2025
Via Benzinga
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
From Summit Therapeutics Inc.
Via Business Wire
3 Stocks That Could Trounce the Market in 2025
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There'
Via Benzinga
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?
Via The Motley Fool
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio?
Via Benzinga
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Why Summit Therapeutics Stock Is Jumping Today
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Via Benzinga
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Via Benzinga
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.